Middle East & AfricaENPublic regulatory overview
Nigeria
Market Overview Population: Approximately 220 million (2024), the most populous country in Africa and the largest economy in Africa by GDP Healthcare System: Predominantly public h...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Nigeria
- Product line: Medical devices
- Regulator / source: Regulatory Maturity: Medium-low; NAFDAC (National Agency for Food and Drug Administration and Control) has a high public profile but limited regulatory capacity; the registration process has relatively low transparency and actual timelines are highly unpredictable
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory Maturity: Medium-low; NAFDAC (National Agency for Food and Drug Administration and Control) has a high public profile but limited regulatory capacity; the registration process has relatively low transparency and actual timelines are highly unpredictable
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 220 million (2024), the most populous country in Africa and the largest economy in Africa by GDP
- Healthcare System: Predominantly public hospitals (Federal Teaching Hospitals, State Hospitals), but infrastructure is generally weak; private healthcare is growing rapidly (especially in Lagos, Abuja, and other major cities); the National Health Insurance Authority (NHIA, consolidating the former NHIS) is advancing Universal Health Coverage; healthcare resources are severely imbalanced between the north and south
- Market Characteristics: A large but fragmented market with non-transparent procurement systems; highly import-dependent (virtually no domestic medical device manufacturing); counterfeit products are a serious problem; numerous private clinics/hospitals; access to foreign exchange (US dollar supply) is a long-standing challenge
- Regulatory Maturity: Medium-low; NAFDAC (National Agency for Food and Drug Administration and Control) has a high public profile but limited regulatory capacity; the registration process has relatively low transparency and actual timelines are highly unpredictable
Regulatory Authority
- Competent Authority: National Agency for Food and Drug Administration and Control (NAFDAC), subordinate to the Federal Ministry of Health (FMOH); the Medical Devices and Packaged Water Directorate handles specific registration matters
- Official Portal: https://www.nafdac.gov.ng; online submission system: NAFDAC Integrated Regulatory Information System (NARIS)
- Key Regulations:
- NAFDAC Act (CAP N1 LFN 2004) and amendments
- Medical Devices (Importation) Regulations
- Food and Drug Administration Act
- NAFDAC Medical Devices Guidelines (multiple versions; review the latest version)
- Federal Ministry of Health Medical Devices Policy
Device Classification System
| Local Class | Risk Level | EU Equivalent | FDA Equivalent | Description |
|---|---|---|---|---|
| Class A | Low risk | EU Class I / FDA Class I | Simplified registration, basic documentation | |
| Class B | Medium risk | EU Class IIa–IIb / FDA Class II | Standard registration; Technical File required | |
| Class C | High risk | EU Class III / FDA Class III | Full registration review; clinical evidence required |
NAFDAC classification follows GHTF classification principles; some device classifications may be inconsistent with international practice — confirm classification with a local consultant before registration. IVDs follow the GHTF IVD classification framework.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.